CAJ | 학술논문

肺癌占恶性肿瘤死因的第一位，其中非小细胞肺癌（NSCLC）占绝大多数。已发现三分之一的NSCLC 和 Kras 基因突变直接相关，故针对 Kras 突变的靶向治疗是近年来肺癌研究的热点。本文从抑制 Kras膜定位、直接抑制 Kras、抑制其下游信号和抑制 Kras 突变的协同致死因子四个方面对目前的研究进展做一简要概论。
폐암점악성종류사인적제일위，기중비소세포폐암（NSCLC）점절대다수。이발현삼분지일적NSCLC 화 Kras 기인돌변직접상관，고침대 Kras 돌변적파향치료시근년래폐암연구적열점。본문종억제 Kras막정위、직접억제 Kras、억제기하유신호화억제 Kras 돌변적협동치사인자사개방면대목전적연구진전주일간요개론。
Lung cancer is the leading cause of malignant tumors,of which most of the cases are non - small cell lung cancer(NSCLC). It has been demonstrated that Kras gene mutation has direct association with one third of lung canc-er cases,therefore these is a great need for new target therapeutic strategies for this disease. Here we review,in the context of NSCLC,the novel target therapies to inhibit four aspects of mutant Kras protein,i. e. membrane association, enzymatic activity,downstream signaling and synthetic lethal targets.